



# Joint Conference Haematopoiesis Immunology & EHOG

«Minimal Residual Disease Diagnosis and Treatment in Tumors of Haematopoietic and Lymphoid Tissues»

# 5 **October 2022**

https://2022.ehog.net/

# **PROGRAM**



## **CHAIRMEN AND SPEAKERS**



NIKOLAI TUPITSYN (RUSSIA) MD, PHD, PROFESSOR HEAD OF THE LABORATORY OF HEMATOPOIESIS IMMUNOLOGY OF BLOKHIN NATIONAL MEDICAL RESEACH CENTER OF ONCOLOGY, MOSCOW, RUSSIAN FEDERATION



GEORGE JANOSSY (UK)
MD, PHD, DSGI, FRCPATH UNIVERSITY COLLEGE LONDON
UCL - DIVISION OF INFECTION AND IMMUNITY, LONDON,
UNITED KINGDOM



ROBERT PETER GALE (USA)
MD, PHD, DSC (HC), FACP, FRCP, FRCPI(HON), FRSM, CENTRE
FOR HAEMATOLOGY, DEPARTMENT OF IMMUNOLOGY AND
INFLAMMATION, IMPERIAL COLLEGE LONDON, LONDON, UK,
DEPARTMENT OF HAEMATOLOGICAL ONCOLOGY, SUN YAT-SEN
CANCER CENTRE, GUANGZHOU, CHINA



DIETER HOELZER (GERMANY)
PROF. MD J.W. GOETHE UNIVERSITY, FRANKFUR, GERMANY
DEPARTMENT OF INTERNAL MEDICINE II, HEMATOLOGY
AND ONCOLOGY, J.W. GOETHE UNIVERSITY HOSPITAL,
ONKOLOGIKUM FRANKFUR, GERMANY



VERA S. DONNENBERG (USA)
PHD, UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE,
DEPARTMENT OF CARDIOTHORACIC SURGERY, PITTSBURGH, PA
UPMC HILLMAN CANCER CENTERS, PITTSBURGH, PA
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE,
PITTSBURGH, PA



TIMUR VALIEV (RUSSIA)
MD, PHD, RESEARCH INSTITUTE OF PEDIATRIC ONCOLOGY
AND HEMATOLOGY OF BLOKHIN NATIONAL MEDICAL RESEACH
CENTER OF ONCOLOGY, MOSCOW, RUSSIAN FEDERATION



JEAN-FRANÇOIS ROSSI (FRANCE)
MD, PHD, UNIVERSITY OF MONTPELLIER, UFR MÉDECINE,
MONTPELLIER, FRANCE, INSTITUT DU CANCER
AVIGNON-PROVENCE, SAINTE CATHERINE-DEPARTMENT OF
HEMATOLOGY-BIOTHERAPY, AVIGNON, FRANCE



KAPITOLINA MELKOVA (RUSSIA) PHD, THE "GUIDE TO HEALTH", CLINIC TWELVE, MOSCOW, RUSSIAN FEDERATION



**VLADIMIR JURISIC** (SERBIA) PROF. MD, PHD, FACULTY OF MEDICAL SCIENCES, UNIVERSITY OF KRAGUJEVAC, SERBIA



MARY SHERVASHIDZE (RUSSIA)
RESEARCH INSTITUTE OF PEDIATRIC ONCOLOGY AND
HEMATOLOGY OF BLOKHIN NATIONAL MEDICAL RESEACH
CENTER OF ONCOLOGY, MOSCOW, RUSSIAN FEDERATION



ALEXANDRA PALLADINA (RUSSIA) LABORATORY OF HEMATOPOIESIS IMMUNOLOGY OF BLOKHIN NATIONAL MEDICAL RESEACH CENTER OF ONCOLOGY, MOSCOW, RUSSIAN FEDERATION



ZHANNA SHAROYAN (RUSSIA) THE "GUIDE TO HEALTH", CLINIC TWELVE, MOSCOW, RUSSIAN FEDERATION

### 09:00 - 09:15 OPENING CEREMONY

PROF. GEORGE JANOSSY (UK) PROF. ROBERT GALE (USA) PROF. NIKOLAI TUPITSYN (RUSSIA)

**CHAIRMEN:** 

PROF. GEORGE JANOSSY (UK) PROF. ROBERT GALE (USA) PROF. DIETER HOELZER (GERMANY) PROF. NIKOLAI TUPITSYN (RUSSIA)

- 09:15 09:35 «SHOULD MRD BE AN ENDPOINT OF CLL THERAPY?» PROF. **ROBERT GALE** (USA)
- 09:35 09:55 «HOW THE EVALUATION OF MINIMAL RESIDUAL DISEASE MAY INFLUENCE A CLINICAL DECISION?» PROF. **JEAN-FRANCOIS ROSSI** (FRANCE)
- 09:55 10:15 «MODERN POSSIBILITIES OF MRD ERADICATION IN ONCOHEMATOLOGY. WHICH ACUTE LEUKEMIA MAY BE TREATED IMMUNOLOGICALLY W/O CHEMOTHERAPY?»
  PROF. **DIETER HOELZER** (GERMANY)
- 10:15 10:35 «LOCALIZED CONDITIONING OF PLEURAL ENVIRONMENT» VERA S. DONNENBERG (USA)
- 10:35 10:55 «GENERAL PRINCIPLES OF MRD MONITORING IN AML» **ALEXANDRA PALLADINA** (RUSSIA)

### 10:55 – 11:10 COFFEE BREAK

- 11:10 11:30 «PROGNOSTIC SIGNIFICANCE OF MRD IN CHILDREN B-ALL AT POST-INDUCTION PERIOD»

  MARY SHERVASHIDZE (CO-AUTHORED WITH ALEXANDRA PALLADINA, TIMUR VALIEV) (RUSSIA)
- 11:30 11:50 «UMBILICAL CORD BLOOD NK-CELLS» **KAPITOLINA MELKOVA** (CO-AUTHORED WITH **ZHANNA SHAROYAN**) (RUSSIA)
- 11:50 12:10 «MODERN APPROACHES TO HEMATOGENEOUS METASTASIS PREVENTION AND CANCER IMMUNE PROPHYLAXIS»
  PROF. NIKOLAI TUPITSYN (RUSSIA)
- 12:10 12:30 «MULTIOMIC CYTOKINE ANALYSIS IN HEMATO-IMMUNOLOGY» VLADIMIR JURISIC (SERBIA)

### 12:30 - 13:00 GENERAL DISCUSSION







### Polyoxidonium® is indicated:



- For prophylaxis of immunodepressive effects of tumors, immunodeficiency correction<sup>1</sup>
- To reduce immunodepressive, hepato- and nephrotoxic effect of chemotherapeutic agents<sup>1</sup>

### Clinical effects of Polyoxidonium®:



- Concomitant use of Polyoxidonium with chemotherapy improves treatment tolerance, reduces the rate of neutropenia, leukopenia, and decreases the incidence of infectious complications  $^{2,3}$
- The use of Polyoxidonium in complex therapy has a pronounced membrane stabilizing effect and prevents the development of hepatic cytolysis syndrome, reducing the hepatotoxic action<sup>4</sup>
- The number of patients who completed all scheduled courses of chemotherapy is significantly higher with the use of Polyoxidonium in supportive therapy<sup>5</sup>

1. INSTRUCTIONS FOR MEDICAL USE OF POLYOXIDONIUM®. AUTHORIZATION NUMBER: P N002935/02 DATED OCTOBER 10, 2008. 2. KOMAROVA L.E., MANZYUK L.V., ARTAMONOVA E.V., FEDENKO A.A. THE EFFECT OF IMMUNOMODULATOR POLYOXIDONIUM ON QUALITY OF LIFE OF BREAST CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER, 2007. 4. CHESNOKOVA N.P., 2004, P. 72–77. 3. FEDENKO A.S. THE INFLUENCE OF SOME IMMUNOMODULATORS ON THE IMMUNE SYSTEM AND THE TOLERABILITY OF ADJUVANT CHEMO- OR CHEMORADIOTHERAPY IN PATIENTS WITH BREAST CANCER, 2007. 4. CHESNOKOVA N.P., BARSUKOV V.Y., ZLOBNOVA O.A., BIZENKOVA M.N. MEMBRANE STABILIZING EFFECT OF POLYOXIDONIUM USE IN COMBINATION TREATMENT OF BREAST CANCER IN THE COURSE OF NEOPLASIA SPREAD/ MODERN PROBLEMS OF SCIENCE AND EDUCATION, NO. 3, 2012. 5. FILONENKO E.V. THESIS FOR A DEGREE OF CANDIDATE OF SCIENCES (MEDICINE). OPTIMIZATION OF CHEMOTHERAPY IN PATIENTS WITH ADVANCED LUNG CANCER. 2004.



+7 (495) 730-75-45 www.petrovax.ru 1, Sosnovaya St., Pokrov village, Podolsk District Moscow Region, 142143, Russia Tel./fax: +7 (495) 329-1817, +7 (495) 926-2107 9-mail: info@petrovax.ru

THE MATERIAL IS INTENDED FOR SPECIALISTS.
BEFORE PRESCRIPTION, READ THE INSTRUCTIONS FOR USE.





